I-CREATE
Financiado
Fighting cancer with next generation oncolytic immunotherapy in ovarian, head &...
Fighting cancer with next generation oncolytic immunotherapy in ovarian, head & neck, and lung cancers (Immune Checkpoint Response Enabling Adenovirus Technology )
TILT Biotherapeutics is a clinical-stage biotechnology company developing novel gene therapies for cancer. TILT’s lead asset, TILT-123, is an oncolytic adenovirus armed with two human cytokines: TNF alpha and IL-2. TILT-123 is now...
TILT Biotherapeutics is a clinical-stage biotechnology company developing novel gene therapies for cancer. TILT’s lead asset, TILT-123, is an oncolytic adenovirus armed with two human cytokines: TNF alpha and IL-2. TILT-123 is now in several Phase 1 clinical trials in Europe, the U.S. and China. The asset has been tailored to immunologically heat up cold tumors. Multiple antitumor mechanisms are activated: direct immunogenic killing of cancer cells while sparing healthy cells, release of tumor epitopes, production of cytokines locally at the tumor, and stimulation of patient’s own immune system to attack cancer. This approach provides the tumor with presence of immune cells: a prerequisite for immune checkpoint inhibitors (ICIs) to work and benefit patients. The project objective is to provide a curative treatment option to patients with refractory cancer, such as the ovarian, head and neck, or lung cancer and secure a global pharmaceutical customer to take TILT-123 to the market.
ver más
Duración del proyecto: 13 meses
Fecha Inicio: 2022-11-11
Fecha Fin: 2023-12-31
Fecha Fin: 2023-12-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
5M€
Líder del proyecto
TILT BIOTHERAPEUTICS OY
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5